ClinicalTrials.gg
CompletedNCT03285984Updated Oct 16, 2018Results posted

Ability of Four Toothpastes to Remove Plaque

An interventional study of 67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride and 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride in Dental Plaque, sponsored by GlaxoSmithKline. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-16.

Sponsored by GlaxoSmithKline · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 5 months after the study started (first participant enrolled Mar 2012, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to evaluate and compare the plaque removal efficacy of four experimental toothpastes following a single timed brushing. Prior to each treatment visit, participants will abstain from oral hygiene for a period of 24 hours (+6hrs, -2hrs), immediately preceding a pre-brushing dental plaque evaluation. Participants will then brush once under supervision for one timed minute with each dentifrice after which re-disclosing and a post-brushing plaque assessment will be carried out.

Read the detailed description

This study will be a single centre, randomized, controlled, examiner blind, four treatment, four period crossover design. At the screening visit, following provision of written informed consent, eligible participants will be provided with a washout toothpaste and toothbrush for use at home during the study and for at least 14 days prior to the first treatment visit.

Participants will then be scheduled to attend the first of four treatment visits a minimum of 14 days later. For each treatment visit, participants must abstain from oral hygiene for a period of 24 hours (+6hrs, -2hrs), immediately preceding the pre-brushing dental plaque evaluation. All the participants will undergo an oral soft tissue (OST) examination followed by disclosing and a dental plaque assessment.

At the treatment visit 1 pre-brushing plaque assessment, those who develop a sufficient amount of plaque (Turesky mean score ≥ 2.00) will be randomized to study treatment. Participants will then brush once (1.5 grams [g] ± 0.05g of assigned toothpaste), under supervision of study staff for one timed minute, with one of the four test toothpastes after which re-disclosing and a post-brushing plaque assessment will be carried out. Participants will be allowed to brush with the washout paste following the post assessment plaque assessments.

A minimum of three days washout period will follow each treatment period during which period Participants will brush with a commercial washout toothpaste. Participants will complete four treatment visits and will brush once with each of the four test toothpastes throughout the course of the study.

02

Conditions studied

  • Dental Plaque

Browse trials for

03

In context

Dental Plaque

353 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.

This study's enrollment of 56 is close to the median of 55 across 317 interventional studies indexed under Dental Plaque.

Browse Dental Plaque studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written and has received a signed and dated copy of the informed consent form.
  • Aged at least 18 years
  • Understands and is willing, able and likely to comply with all study procedures and restrictions
  • Good general health with (in the opinion of the Investigator) no and relevant abnormalities of medical history or dental history.
  • Good dental health based on medical history and oral soft tissue examination at screening
  • At least 20 gradable, natural, uncrowned teeth with both facial and lingual scoreable surfaces (gradable teeth are those where restorative materials cover less than 25% of the tooth surface graded)
  • Plaque Score: Mean Turesky plaque score of ≥ 2.00 at treatment visit 1 pre-brushing plaque assessment

Exclusion criteria

Exclusion Criteria:

  • Women who are known to be pregnant or who are intending to become pregnant over the duration of the study
  • Women who are breast-feeding
  • Antibiotic treatment within 14 days prior to Treatment Visit 1 or throughout the study
  • Any other treatment that would interfere with the study results/conduct, at the discretion of the examiner or investigator
  • Diabetes mellitus type I or II
  • Any disease systemic or localized, dental or non dental, which could put the participant's health at risk or interfere with the study results/conduct, at the discretion of the examiner or investigator
  • High levels of extrinsic stain or calculus deposits which might interfere with plaque assessments
  • Dental condition/ disease requiring immediate treatment
  • Pre-existing sensitivity to oral care products
  • Severe gingivitis
  • Periodontitis with pocket depth > 5mm affecting more than two teeth
  • Moderate or severe recession
  • Presence of orthodontic bands or appliances, extensive crowns, partial dentures, or fixed retainers on the maxillary or mandibular teeth
  • Obvious active carious lesions needing immediate care
  • Intra-oral decorative tattoos, or tongue and or lip piercing
  • Oral lesions/manifestations that would impact on the outcome of the study
  • Presence of oral or peri-oral ulceration including herpetic lesions at the time of screening or at baseline
  • Known or suspected intolerance or to the studymaterials (or closely related compounds) or any of their stated ingredients
  • Participation in another clinical study or receipt of an drug within 30 days of the screening visit
  • Previous participation in this study
  • Recent history (within the last year) of alcohol or other substance abuse
  • Current use of Listerine or any antimicrobial mouth rinse containing Chlorhexidine or Cetrylpyridinium Chloride (CPC)
  • Participant unwilling to abstain from using chewing tobacco (with or without tobacco)
  • Participant unwilling to abstain from smoking on the morning prior to treatment visits
  • An employee of the sponsor or the study site or members of their immediate family
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Test product 1

    Participants will brush once (1.5g ± 0.05g of Test product 1), under supervision of study staff for one timed minute

    Other: 67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride

  • Experimental
    Test product 2

    Participants will brush once (1.5g ± 0.05g of Test product 2), under supervision of study staff for one timed minute

    Other: 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride

  • Experimental
    Test product 3

    Participants will brush once (1.5g ± 0.05g of Test product 3), under supervision of study staff for one timed minute

    Other: 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium

  • Experimental
    Test product 4

    Participants will brush once (1.5g ± 0.05g of Test product 4), under supervision of study staff for one timed minute

    Other: 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride

Interventions

  • Other67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride

    Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride

  • Other67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride

    Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride

  • Other62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium

    Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium

  • Other0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride

    Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline (Pre-brushing to Post-brushing) in Turesky Score After Single Supervised Use (Test Product 1 Versus [vs] Test Product 4) After 4 Weeks

    The dental examiner used Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth.Overall plaque scores were calculated taking average over all tooth sites for participant.Plaque was first disclosed using dye solution followed by disclosing solution.They expectorated and rinsed with 10 milliliters (mL) water for 10 seconds (sec),expectorated again. Plaque was assessed with each tooth being divided into 6 areas including mesiofacial,facial,distofacial,mesiolingual,lingual,distolingual surfaces.Disclosed plaque was scored for each tooth surface separately as:0 No plaque;1 Slight flecks of plaque at cervical margin of the tooth;2 A thin continuous band of plaque(1 mm or smaller) at cervical margin of tooth;3 A band of plaque wider than 1 mm but covering less than 1/3 of the crown of tooth;4 Plaque covering at least 1/3 but less than 2/3 of crown of tooth;5 Plaque covering 2/3 or more of crown of tooth.Score range 0-5.Lower scores indicate less plaque area.

    Time frame: Baseline to 4 Weeks

Secondary outcomes

  1. Mean Change From Baseline (Pre-brushing to Post Brushing) in Turesky Score After Single Supervised Use for Test Products 1, 2, 3 and 4 After 4 Weeks

    The dental examiner used Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth.Overall plaque scores were calculated taking average over all tooth sites for participant.Plaque was first disclosed using dye solution followed by disclosing solution.They expectorated and rinsed with 10 mL of water for 10 sec,expectorated again. Plaque was assessed with each tooth being divided into 6 areas including mesiofacial,facial,distofacial,mesiolingual,lingual,distolingual surfaces.Disclosed plaque was scored for each tooth surface separately as:0 No plaque;1 Slight flecks of plaque at cervical margin of the tooth;2 A thin continuous band of plaque(1 mm or smaller) at cervical margin of tooth;3 A band of plaque wider than 1 mm but covering less than 1/3 of the crown of tooth;4 Plaque covering at least 1/3 but less than 2/3 of crown of tooth;5 Plaque covering 2/3 or more of crown of tooth.Score range 0-5.Lower scores indicate less plaque area.

    Time frame: Baseline to 4 Weeks

07

Results

Posted Oct 16, 2018

Participant flow

Participants were recruited at a single center in the United States.

Participant flow — Overall Study
MilestoneOverall Study
Started56
Received test product 156
Received test product 256
Received test product 356
Received test product 456
Completed56
Not completed0

Outcome measures

PrimaryMean Change From Baseline (Pre-brushing to Post-brushing) in Turesky Score After Single Supervised Use (Test Product 1 Versus [vs] Test Product 4) After 4 Weeks

The dental examiner used Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth.Overall plaque scores were calculated taking average over all tooth sites for participant.Plaque was first disclosed using dye solution followed by disclosing solution.They expectorated and rinsed with 10 milliliters (mL) water for 10 seconds (sec),expectorated again. Plaque was assessed with each tooth being divided into 6 areas including mesiofacial,facial,distofacial,mesiolingual,lingual,distolingual surfaces.Disclosed plaque was scored for each tooth surface separately as:0 No plaque;1 Slight flecks of plaque at cervical margin of the tooth;2 A thin continuous band of plaque(1 mm or smaller) at cervical margin of tooth;3 A band of plaque wider than 1 mm but covering less than 1/3 of the crown of tooth;4 Plaque covering at least 1/3 but less than 2/3 of crown of tooth;5 Plaque covering 2/3 or more of crown of tooth.Score range 0-5.Lower scores indicate less plaque area.

Time frame:
Baseline to 4 Weeks
Reported as:
Mean · Score on a scale
Mean Change From Baseline (Pre-brushing to Post-brushing) in Turesky Score After Single Supervised Use (Test Product 1 Versus [vs] Test Product 4) After 4 Weeks
Score on a scaleTest Product 1Test Product 4
Baseline2.90 ± 0.3082.86 ± 0.309
Post Baseline1.76 ± 0.5141.96 ± 0.470
Change from Baseline-1.13 ± 0.430-0.90 ± 0.409
Statistical analysis
  • Test Product 1 vs Test Product 4 · ANCOVA · p = <.0001 (From ANCOVA model with factors for treatment group, period and subject (random effect), and subject-level baseline and period-level baseline) · Mean difference (net): -0.21 · 95% CI -0.27 to -0.15Difference is first named treatment minus second-named treatment such that a negative difference favors the first named treatment
SecondaryMean Change From Baseline (Pre-brushing to Post Brushing) in Turesky Score After Single Supervised Use for Test Products 1, 2, 3 and 4 After 4 Weeks

The dental examiner used Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth.Overall plaque scores were calculated taking average over all tooth sites for participant.Plaque was first disclosed using dye solution followed by disclosing solution.They expectorated and rinsed with 10 mL of water for 10 sec,expectorated again. Plaque was assessed with each tooth being divided into 6 areas including mesiofacial,facial,distofacial,mesiolingual,lingual,distolingual surfaces.Disclosed plaque was scored for each tooth surface separately as:0 No plaque;1 Slight flecks of plaque at cervical margin of the tooth;2 A thin continuous band of plaque(1 mm or smaller) at cervical margin of tooth;3 A band of plaque wider than 1 mm but covering less than 1/3 of the crown of tooth;4 Plaque covering at least 1/3 but less than 2/3 of crown of tooth;5 Plaque covering 2/3 or more of crown of tooth.Score range 0-5.Lower scores indicate less plaque area.

Time frame:
Baseline to 4 Weeks
Reported as:
Mean · Score on a scale
Mean Change From Baseline (Pre-brushing to Post Brushing) in Turesky Score After Single Supervised Use for Test Products 1, 2, 3 and 4 After 4 Weeks
Score on a scaleTest Product 1Test Product 2Test Product 3Test Product 4
Baseline2.90 ± 0.3082.92 ± 0.3122.89 ± 0.3042.86 ± 0.309
Post Baseline1.76 ± 0.5141.78 ± 0.4921.77 ± 0.4691.96 ± 0.470
Change from Baseline after 4 weeks-1.13 ± 0.430-1.14 ± 0.426-1.11 ± 0.419-0.90 ± 0.409

Adverse events

Collected over Approximately 15 days (from Screening Visit to 5 days following last visit [Visit 4]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product 10/56 (0%)0/56 (0%)0/56 (0%)
Test Product 20/56 (0%)0/56 (0%)0/56 (0%)
Test Product 30/56 (0%)0/56 (0%)0/56 (0%)
Test Product 40/56 (0%)0/56 (0%)0/56 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Randomized Participants
Mean44.1 ± 11.87
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Participants
Female36
Male20
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Randomized Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White51
More than one race0
Unknown or Not Reported0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bosma ML, Milleman KR, Akwagyiram I, Targett D, Milleman JL. A randomised controlled trial to evaluate the plaque removal efficacy of sodium bicarbonate dentifrices in a single brushing clinical model. BDJ Open. 2018 Jun 4;4:17037. doi: 10.1038/s41405-018-0003-7. eCollection 2018. PubMed 29971158 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in May 2012, 1 month.

Results were first posted in Oct 2018, 6 years 5 months after primary completion.

Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 1 month is below that.

Counting every sponsor, half of 179 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2017
First posted
Sep 18, 2017
StartActual
Mar 27, 2012
Primary completionActual
May 8, 2012
CompletionActual
May 8, 2012
Results first posted
Oct 16, 2018
Last update
Oct 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03285984
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 18, 2017
Start date
Mar 27, 2012
Primary completion
May 8, 2012
Completion
May 8, 2012
Results posted
Oct 16, 2018
Last update
Oct 16, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion